Popular terms

Quinoline topics
Isoquinolin
Praziquantel
Carbon Atoms
Crystallin
Quinoline Derivatives
Pharmaceutically Acceptable Salt
Alkyl Group
Cycloalkyl
Pharmaceutically Acceptable Salts
Immunodeficiency
Retrovirus
Viral Infection
Human Immunodeficiency Virus
Angiogenesis
Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Quinoline patents



      

This page is updated frequently with new Quinoline-related patent applications.




Date/App# patent app List of recent Quinoline-related patents
04/07/16
20160096807 
 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator patent thumbnailCo-crystals of modulators of cystic fibrosis transmembrane conductance regulator
The present disclosure relates to co-crystals comprising n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits..
Vertex Pharmaceuticals Incorporated


04/07/16
20160096806 
 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition patent thumbnail2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.. .

04/07/16
20160095849 
 Crystalline form of a quinolinone-carboxamide compound patent thumbnailCrystalline form of a quinolinone-carboxamide compound
The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1s,3r,5r)-8-[(r)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-ht4 receptor activity, and processes useful for preparing such crystalline salt forms..
Theravance Biopharma R&d Ip, Llc


03/24/16
20160083671 
 Polyalkylene glycol-based industrial lubricant compositions patent thumbnailPolyalkylene glycol-based industrial lubricant compositions
A lubricant composition comprises as a lubricant base, an oil soluble polyalkylene glycol suitable for use as a lubricant in an industrial oil, grease or metal working fluid; and an additive comprising (1) alkylated phenyl-α-naphthylamine; and (2) 2,2,4-trialkyl-1,2-dihydroquinoline.. .
Vanderbilt Chemical, Llc


03/24/16
20160083385 
 Pyrazinoisoquinoline compounds patent thumbnailPyrazinoisoquinoline compounds
Where the designation (r) indicates that the designated carbon has the (r) stereochemistry; and wherein z1 is hydrogen or fluorine; z2 is hydrogen, deuterium, or fluorine; z3 is deuterium; z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both z1 and z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel..

03/24/16
20160083351 
 Tetrahydroisoquinolines as selective nadph oxidase 2 inhibitors patent thumbnailTetrahydroisoquinolines as selective nadph oxidase 2 inhibitors
Wherein “” represents a single or double bond, r1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; ra is hydrogen, —ch2r2, r3, or —so2r4; r2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; r3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; r4 is lower aliphatic, or substituted or unsubstituted aryl; and r5 is hydrogen, halogen, or lower aliphatic.. .

03/24/16
20160081999 
 Synthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1) - topoisomerase i (top1) inhibitors patent thumbnailSynthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1) - topoisomerase i (top1) inhibitors
The invention described herein pertains to the synthesis and use of certain n-substituted indenoisoquinoline compounds which inhibit the activity tyrosyl-dna phosphodiesterase i (tdp1) or topoisomerase i (top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel n-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel n-substituted indenoisoquinoline compounds..
Purdue Research Foundation


03/17/16
20160075715 
 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors patent thumbnailSubstituted tetrahydroisoquinoline compounds as factor xia inhibitors
Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

03/17/16
20160075700 
 Yellow reduced pyrroloquinoline quinone crystal and  producing the same, and food, pharmaceutical, gel, composition and  producing composition patent thumbnailYellow reduced pyrroloquinoline quinone crystal and producing the same, and food, pharmaceutical, gel, composition and producing composition
A yellow reduced pyrroloquinoline quinone crystal having a solubility in water of 0.040 to 0.20 (mg/ml).. .
Mitsubishi Gas Chemical Company, Inc.


03/17/16
20160075688 
 New 3,4-dihydro-2h-isoquinoline-1-one and  2,3-dihydro-isoindol-1-one compounds patent thumbnailNew 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, a, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075687 

New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds


Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, a, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075686 

New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds


Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, a, b, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075657 

Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof


Wherein r1 to r6, n and m are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.. .

03/17/16
20160075656 

Quinoline amide m1 receptor positive allosteric modulators


The present invention is directed to quinoline amide compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositious comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.


03/17/16
20160074377 

Substituted naphthyridine and quinoline compounds as mao inhibitors


Wherein r1, r2, r3, y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting mao, and mao-b selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a cns disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.. .

03/03/16
20160060270 

New aryl-quinoline derivatives


Wherein r1, r2, r3, r4, r5, r6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (fabp) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases..

03/03/16
20160060263 

Pyrazinoisoquinoline compounds


This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
Concert Pharmaceuticals, Inc.


03/03/16
20160060222 

Amino-quinolines as kinase inhibitors


Wherein r1, r2 and a are as defined herein, and methods of making and using the same.. .

03/03/16
20160058749 

Treatments for neuropathy


Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (gdnf) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions..
Children's Medical Center Corporation


02/25/16
20160052889 

Phenoxyethyl dihydro-1h-isoquinoline compounds


The present invention provides a compound of the formula i: wherein r is h or f; or a pharmaceutically acceptable salt thereof.. .
Eli Lilly And Company


02/25/16
20160051534 

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8- tetrahydro-quinoline for treating skin diseases and conditions


The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. .
Allergan, Inc.


02/18/16
20160046623 

Salt of pyrazoloquinoline derivative, and crystal thereof


The present invention provides a salt of (s)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1h-pyrazolo[4,3-c]quinolin-4(5h)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals.. .
Eisai R&d Management Co., Ltd.


02/18/16
20160046603 

Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate


The present disclosure relates generally to crystalline forms of anhydrous d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1- yl)-4-oxo-3-quinolinecarboyxlate, compositions comprising the same, and methods of making the same. Delafloxacin is an fluoroquinolone antibiotic with the chemical structure and the chemical name 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboyxlate.
Melinta Therapeutics, Inc.


02/18/16
20160046583 

Isoquinoline derivatives


For the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.. .

02/18/16
20160045489 

N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors


The present invention relates to novel n-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.. .
Allergan, Inc.


02/18/16
20160045447 

Piperaquine microcapsules and compositions containing them


The present invention provides a microcapsule pharmaceutical composition of at least a bisquinoline drug. Said microcapsule comprises a drug core of a pharmaceutically effective amount of a bisquinoline drug and a polymeric coating over the core.
Adare Pharmaceuticals S.r. L.


02/11/16
20160039816 

Crystals of pyrroloquinolinequinone sodium salts


A crystal of pyrroloquinoline quinone disodium salt having peaks at 2θ of 9.1°, 10.3°, 13.8°, 17.7°, 18.3°, 24.0°, 27.4°, 31.2° and 39.5° (±0.2° for each) in powder x-ray diffractometry using cu kα radiation, or a crystal of pyrroloquinoline quinone trisodium salt having peaks at 2θ of 6.6°, 11.4°, 13.0°, 22.6°, 26.9°, 27.9°, 37.0°, 38.9° and 43.4° (±0.2° for each) in powder x-ray diffractometry using cu kα radiation.. .
Mitsubishi Gas Chemical Company, Inc.


02/11/16
20160039786 

Method for producing 3,4-dihydroisoquinoline derivatives and production intermediates of same


Provided are an efficient method for producing 3,4-dihydroisoquinoline derivatives and useful production intermediates thereof. Provided is a method for producing 3,4-dihydroisoquinoline derivatives represented by general formula (1), comprising converting a compound represented by general formula (3) in the presence of acid after reacting with an aniline derivative, or converting a compound represented by general formula (3) by reacting with an aniline derivative in the presence of an acid..
Mitsui Chemicals Agro, Inc.


02/11/16
20160038503 

Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives


The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell lymphoma).

02/11/16
20160038478 

Composition and methods for treating skin conditions


Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.. .
442 Ventures, Llc


02/04/16
20160030416 

Methods of treating b2-bradykinin receptor mediated angioedema


Methods of treating b2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the treatment of b2-bradykinin receptor mediated angioedema.
Shire Human Genetic Therapies, Inc.


02/04/16
20160030414 

Benzoquinoline inhibitors of vmat 2


The present invention relates to new benzoquinolone inhibitors of vmat2, pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.


01/28/16
20160022675 

Processes for preparing tetrahydroisoquinolines


Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and compositions comprising the tetrahydroisoquinolines and other compounds, e.g, intermediates and by-products of the processes described herein. Pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression are also disclosed..
Bristol-myers Squibb Company


01/21/16
20160016954 

Tricyclic quinoline and quinoxaline derivatives


The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
Abbvie Deutschland Gmbh & Co. Kg


01/21/16
20160016951 

Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors


The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cdk8/19, and for the treatment of cdk8/19-related disorders.. .
Cancer Research Technology, Ltd.


01/21/16
20160016933 

Isoquinolines as potassium ion channel inhibitors


A compound of formula (i) (i) wherein a, r1, r1a, r3 and r24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, ikur-associated disorders, and other disorders mediated by ion channel function..
Bristol-myers Squibb Company


01/21/16
20160016908 

2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors


The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.. .
Glaxosmithkline Intellectual Property (no.2) Limited


01/14/16
20160009653 

Cyanoisoquinoline compounds and methods of use thereof


The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/07/16
20160002207 

New dihydroquinoline-2-one derivatives


Wherein r1, r2, r3, r4, r5, r6, r7, r9, r10, r11 and a are as described herein, compositions including the compounds and methods of using the compounds.. .

01/07/16
20160002170 

Crystalline forms of -acetic acid


The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (compound a), the process of preparing crystalline forms of compound a, the pharmaceutical compositions containing them, and the methods of use thereof.. .
Fibrogen, Inc.


01/07/16
20160002168 

Use of quinoline derivatives for improving plant yield


Compounds (a) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the compound (a) is selected from compounds of the formula (i) and hydrates or salts thereof,. .
Bayer Cropscience Ag


12/31/15
20150376186 

Quinoline derivatives as pde10a enzyme inhibitors


The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10 over other pde subtypes.
H. Lundbeck A/s


12/31/15
20150376180 

Dihydroquinoline-2-one derivatives


Wherein r1, r2, r3, r4, r5, r6, r7, r9, r10 and r11 are as described herein, compositions including the compounds and methods of using the compounds.. .

12/31/15
20150376133 

C-met modulators and methods of use


The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-met, kdr, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
Exelixis, Inc.


12/31/15
20150376132 

Quinoline sulfonyl derivatives and uses thereof


The present disclosure relates to quinoline sulfonyl compounds, compositions comprising these compounds and their use, in particular for the treatment of cancer. In particular, the present disclosure includes compounds of formula (i), and compositions and uses thereof:.
Advanced Medical Research Institute Of Canada


12/24/15
20150366877 

Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors


Methods of inhibiting replication of human cytomegalovirus (hcmv) are disclosed. In various configurations, these methods comprise administering a therapeutically effective amount of a bromodomain inhibitor to a subject in need thereof.
Washington University


12/17/15
20150364702 

Iridium complex and organic light-emitting device including the same


The present invention provides a novel iridium complex and an organic light-emitting device including the novel iridium complex. The novel iridium complex includes three ligands, and two of them have a phenyl-naphtho[2,1-f]isoquinoline skeleton.
Canon Kabushiki Kaisha


12/17/15
20150361044 

Stable crystal of 4-oxoquinoline compound


Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(s)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound a). A crystal of compound a, which shows a particular x-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by x-ray powder diffractometry..
Japan Tobacco Inc.


12/10/15
20150353498 

Substituted isoquinolines as crth2 receptor modulators


The invention provides certain substituted isoquinolines of the formula (i), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
Merck Sharp & Dohme Corp.


12/10/15
20150353497 

Novel quinoline derivatives and their use in neurodegenerative diseases


The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of p2x7, and for the treatment of p2x7-related disorders.. .
Merck Patent Gmbh


12/10/15
20150352098 

Substituted pyrano and furanoquinolines, their preparation and use as medicaments


The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.. .
Laboratorios Del Dr. Esteve S.a.


12/03/15
20150344522 

Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof


The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.. .

12/03/15
20150344491 

[1,3] dioxolo [4,5-g] quinoline-6(5h)thione derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer


The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. Hepatocellular carcionoma (hcc).
Trustees Of Boston University


12/03/15
20150344434 

Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


12/03/15
20150344433 

Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


12/03/15
20150342945 

Substituted quinoline compounds and methods of use


The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.


11/26/15
20150336947 

Pyrroloquinoline alkaloids as antimalarial agents and process for the preparation thereof


The patent provides novel compounds with potential anti-malarial activity and process of synthesis thereof. Further, the process for the synthesis of known antimalarial natural products marinoquinazolinone a-f, aplidiopsamine a and their potential antimalarial analogues is disclosed..
Council Of Scientific & Industrial Research


11/26/15
20150336945 

Quinoline and quinazoline amides as modulators of sodium channels


The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.. .

11/26/15
20150336897 

Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors


The present invention is directed to novel quinoline compounds useful as s-nitrosoglutathione reductase (gsnor) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.. .
Nivalis Therapeutics, Inc.


11/26/15
20150335646 

Pyrimido[4,5-b]quinoline-4,5(3h,10h)-diones


The invention relates to compound of the formula (i); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.. .
Novartis Ag


11/26/15
20150335636 

Novel substituted imidazoquinolines


Imidazoquinolines of formula i that contain substituted amine or amide functionality at 1-position and that are effective as toll like receptor 7 activators are disclosed. These compounds are useful as anticancer agents..
4sc Ag


11/26/15
20150335635 

8-hydroxy quinoline derivatives


Or pharmaceutically acceptable salts, hydrates, or solvates thereof.. .

11/26/15
20150335634 

Isoquinoline alkaloid derivative for activating amp-dependent protein kinase


The present invention provides a method for activating the amp-dependent protein kinase (ampk) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general formula i, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate ampk, and thus is effective in the regulation of cell growth and metabolism, and the treatment of ampk associated diseases..
Zih Yuan Tang Biotechnology Co., Ltd


11/19/15
20150333279 

Organic light-emitting element and display apparatus


Provided is an organic light-emitting element having high luminous efficiency and a long lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a metal complex compound of a specific structure..
Canon Kabushiki Kaisha


11/19/15
20150329498 

Irak inhibitors and uses thereof


The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of irak enzymes..
Nimbus Iris, Inc.


11/19/15
20150328207 

Benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.


11/12/15
20150322015 

Crystalline forms of a prolyl hydroxylase inhibitor


The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.


11/12/15
20150320742 

Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline


C) paediatric disorders e.g. Autism, mental retardation and learning disabilities..

11/05/15
20150315200 

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors


Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

11/05/15
20150315184 

4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor


Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
Glaxosmithkline Llc


10/29/15
20150307490 

Process for the preparation of moxifloxacin hydrochloride


The present invention relates to an improved and industriously advantageous process by means of providing coupling/condensing of wet mass of (1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid-o3,o4)bis(acyloxy-o)borate with (s,s)-2,8-diazabicyclo[4.3.0]nonane to give 1-cyclopropyl-7-[s,s]-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride (moxifloxacin hydrochloride) of formula-i with high purity.. .
Mankind Research Centre


10/29/15
20150307453 

Novel quinoline derivatives and their applications


The invention relates to a series of quinoline derivatives of general formula i, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof m, r1, r2, x, y and n are defined as claims.
Shenyang Pharmaceutical University


10/22/15
20150303386 

Organic light-emitting device and display apparatus


Provided is an organic light-emitting device improved in emission efficiency and lifetime. The organic light-emitting device includes a pair of electrodes and an organic compound layer disposed between the pair of electrodes, in which: the organic compound layer includes a benzo[f]isoquinoline iridium complex of a specific structure and a hydrocarbon compound of a specific structure; and the hydrocarbon compound is a compound formed only of an sp2 carbon atom and a hydrogen atom..
Canon Kabushiki Kaisha


10/22/15
20150299246 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services


10/22/15
20150299194 

4-amino-imidazoquinoline compounds


Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases..

10/22/15
20150299159 

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds


Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.


10/22/15
20150299104 

Method for producing 4-oxoquinoline compound


Wherein r is a fluorine atom or a methoxy group, and r400 is a hydrogen atom or a c1-c4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-hiv agent using the synthetic intermediate.. .

10/22/15
20150296779 

Substituted dihydropyridines for somatic embryogenesis in plants


Cyclopentyl 2,7,7-trimethyl-5-oxo-4-(4-pyridinyl)-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate and similar compounds are potentiators of auxin-induced somatic embryogenesis in plants. In particular, the inventors have discovered certain of these compounds induce somatic embryogenesis in arabidopsis in the presence of 2,4-d.
Stichting Dienst Landbouwkundig Onderzoek


10/15/15
20150295188 

Organic light-emitting element


Provided is an organic light-emitting element improved in luminous efficiency and lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a heterocycle-containing compound of a specific structure..

10/15/15
20150291583 

Crystalline forms of pyrroloquinoline quinone disodium salt


The present invention relates to crystalline forms of pyrroloquinoline quinone disodium salt. The present invention provides crystalline form a and crystalline form b of pyrroloquinoline quinone disodium salt, and the methods and uses for the preparation thereof.

10/15/15
20150291532 

Amorphous form of quinoline derivative, and producing same


The invention provides an amorphous form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.. .



Quinoline topics: Isoquinolin, Praziquantel, Carbon Atoms, Crystallin, Quinoline Derivatives, Pharmaceutically Acceptable Salt, Alkyl Group, Cycloalkyl, Pharmaceutically Acceptable Salts, Immunodeficiency, Retrovirus, Viral Infection, Human Immunodeficiency Virus, Angiogenesis, Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.031

4778

2 - 1 - 101